New Onset Depressive Symptoms in Acute Illness (R01 Clinical Trial Not Allowed) | PA 17 488

Opportunity Information: Apply for PA 17 488

The National Institutes of Health (NIH) funding opportunity titled "New Onset Depressive Symptoms in Acute Illness (R01 Clinical Trial Not Allowed)" (Funding Opportunity Number: PA-17-488) supports research that explains why depressive symptoms newly appear during or after a sudden, acute medical illness. The central focus is not on treating depression through an intervention trial, but on understanding causes and underlying mechanisms. NIH is highlighting a practical clinical problem: many patients experience depressive symptoms after an acute health event, and those symptoms can persist well beyond the point when the body has largely recovered. When that happens, depression can interfere with rehabilitation, daily function, and overall recovery trajectory. Even though this pattern is widely recognized in clinical practice, the biological and etiological pathways that drive these newly emerging symptoms in the setting of acute illness are still not well understood. This FOA is meant to close that gap by encouraging studies that identify the pathobiology and contributing factors behind incident depressive symptoms tied specifically to acute insults.

The FOA frames "acute illness" as a sudden-onset event or condition that can disrupt physical functioning and trigger stress responses in the body and brain. The research emphasis is on etiology, meaning applicants are expected to investigate origins and mechanisms rather than simply document prevalence or test a clinical treatment. Projects might examine how inflammatory responses, immune signaling, neuroendocrine changes (such as stress hormone dysregulation), autonomic nervous system shifts, vascular or metabolic changes, pain pathways, sleep disruption, medication effects, or other physiological consequences of acute illness relate to the onset and course of depressive symptoms. Another strong theme is heterogeneity: not everyone exposed to a similar medical event develops depressive symptoms, and among those who do, symptom patterns and persistence vary. The announcement encourages work that explains why some people develop depression-like symptoms while others remain resilient, and what factors shape whether symptoms resolve quickly or become longer-lasting and recovery-limiting.

A key goal is to improve understanding of symptom trajectories over time. Rather than treating depressive symptoms as a single static outcome, the FOA points toward studying how symptoms evolve from the acute phase through convalescence, and how those patterns relate to functional recovery. Research responsive to this announcement would typically include careful phenotyping of depressive symptoms, attention to timing relative to the medical insult, and measurement of relevant biological, clinical, and contextual factors that could plausibly influence risk or protection. By clarifying which etiological factors contribute to, worsen, or mitigate new-onset depressive symptoms after acute illness, NIH is aiming to build a foundation for more personalized and holistic approaches to recovery management, where mental health risk can be anticipated and addressed as part of the broader post-illness care plan.

This is an R01 grant mechanism, which generally supports substantial, investigator-initiated research programs. The FOA is explicitly labeled "Clinical Trial Not Allowed," meaning applications should not propose prospective assignment of human participants to an intervention to evaluate health outcomes. Observational human studies, mechanistic studies, analyses of existing cohorts or datasets, or other non-trial designs that probe causes and pathways are generally more aligned with this restriction, as long as they do not meet NIH’s definition of a clinical trial.

Eligibility is broad. In addition to typical applicants such as public and private institutions of higher education, nonprofits, for-profits (other than small businesses), small businesses, and various levels of government (state, county, city or township, special districts), the FOA explicitly notes additional eligible applicant types. These include Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), Indian/Native American Tribal Governments (other than federally recognized), faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions. Non-U.S. entities (foreign organizations) are also listed as eligible, signaling NIH’s openness to strong international research programs where appropriate.

Administrative details included in the source information indicate this is a discretionary grant opportunity administered by NIH, categorized under education and health funding activity areas, with CFDA numbers 93.242 and 93.361. The FOA record shows a creation date of 2017-09-19 and an original closing date of 2021-01-07 in the provided listing. No award ceiling or expected number of awards is specified in the excerpt, which typically means applicants would need to consult the full FOA text and NIH institute or center guidance to understand budget expectations, standard R01 limits, and paylines or likely award volumes.

Overall, this opportunity is designed for investigators who can bring together clinical insight and biological or behavioral science to explain how and why depressive symptoms emerge in the wake of acute illness, why those symptoms sometimes persist, and how that knowledge can ultimately support more individualized recovery care even though the funded work itself should not be an intervention clinical trial.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "New Onset Depressive Symptoms in Acute Illness (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242, 93.361.
• This funding opportunity was created on 2017-09-19.
• Applicants must submit their applications by 2021-01-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PA 17 488

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: